A Brief Provider Training Video Improves Comfort With Recommending the Human Papillomavirus Vaccine

2018 ◽  
Vol 58 (1) ◽  
pp. 17-23 ◽  
Author(s):  
Maya M. Kumar ◽  
Eyla G. Boies ◽  
Mark H. Sawyer ◽  
Meredith Kennedy ◽  
Christine Williams ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Cost Effective ◽  
Human Papillomavirus Vaccine ◽  
Vaccine Response ◽  
Training Video ◽  
Clinical Vignettes ◽  
Training Modality ◽  
Vaccine Completion ◽  
Papillomavirus Vaccine

The American Academy of Pediatrics California Chapter 3 created a 20-minute training video targeting barriers to strong provider recommendation of the human papillomavirus (HPV) vaccine. The video included clinical vignettes featuring pediatricians modeling counseling techniques with vaccine-hesitant families. Ninety-six multidisciplinary providers (including pediatric residents) at 6 sites viewed the video and completed baseline and posttest questionnaires assessing their vaccine knowledge, attitudes toward vaccination, and comfort with skills needed to facilitate vaccination. Following the intervention, providers had substantial and statistically significant ( P < .05) improvements in multiple areas assessed, particularly knowledge of the burden of HPV-related disease in males and changes in vaccine response with age; likelihood of “strongly agreeing” that vaccination should not be delayed beyond preadolescence and that HPV vaccine is safe; and feeling “very comfortable” counseling vaccine-hesitant parents and facilitating vaccine completion. This cost-effective and easily disseminated training modality shows promise in increasing provider comfort with HPV vaccine counseling.

scholarly journals Barriers to Human Papillomavirus Vaccine Series Completion among Insured Individuals in an Integrated Healthcare Setting

2021 ◽  
Vol 14 ◽  
pp. 117863372110187
Author(s):  
Aruna Kamineni ◽  
Paula R Blasi ◽  
Gabrielle D Gundersen ◽  
Malia Oliver ◽  
John B Dunn ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Cancer Prevention ◽  
Hpv Vaccine ◽  
Healthcare Setting ◽  
Human Papillomavirus Vaccine ◽  
Dose Requirement ◽  
Integrated Healthcare ◽  
Vaccine Completion ◽  
Series Completion ◽  
Papillomavirus Vaccine

Introduction: Infection with certain types of human papillomavirus (HPV) can lead to cervical cancer as well as other cancers in both men and women. However, the requirement for multiple doses may limit the vaccine’s effectiveness for cancer prevention. We conducted a pilot study to investigate barriers to HPV vaccine series completion among members of an integrated healthcare system with clinical documentation of only 1 dose. Methods: We surveyed parents or legal guardians of 11-17-year-old girls (n = 10) and boys (n = 18), as well as 18-31-year-old women (n = 20) and men (n = 9), about their reasons for not completing the HPV vaccine series. Results: Most participants (70.2%) were non-Hispanic white. Among parents of children, commonly reported barriers to HPV vaccine series completion included not being aware or informed of the need for additional doses (28.6%), as well as the inconvenience of returning for additional doses (17.9%). Concerns about the HPV vaccine or vaccines in general were more common among parents of girls (30.0%) compared with parents of boys (16.7%). Among adults, barriers to HPV vaccine series completion included the inconvenience of returning for additional doses (31.0%), not being aware or informed of the need for additional doses (10.3%), and forgetting (10.3%). Conclusion: Our findings suggest that clinicians and healthcare systems can play a greater role in promoting awareness of the multiple-dose requirement, addressing vaccine concerns, and increasing opportunistic vaccination in a variety of settings. Increasing these efforts may facilitate HPV vaccine completion and increase its effectiveness in cancer prevention.

Vaccine Hesitancy and Differential Susceptibility to Media Coverage: A Critical Documentary Led to Substantial Reductions in Human Papillomavirus Vaccine Uptake in Denmark

2021 ◽  
pp. 0272989X2110035
Author(s):  
Maria Knoth Humlum ◽  
Niels Skipper ◽  
Peter Rønø Thingholm
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Media Coverage ◽  
Differential Susceptibility ◽  
Vaccine Uptake ◽  
Vaccine Hesitancy ◽  
Human Papillomavirus Vaccine ◽  
Policy Makers ◽  
Quasi Experimental ◽  
Papillomavirus Vaccine

Objectives To investigate whether negative media coverage of the human papillomavirus (HPV) vaccine led to a decrease in the uptake of the first dose of the HPV vaccine (HPV1) in Denmark and, importantly, whether some groups of individuals were more susceptible to negative media coverage. Methods We measured HPV vaccine uptake of 12-year-old girls born in 2001 to 2004 using Danish administrative data. A quasi-experimental design was employed to assess whether a documentary that was critical of the HPV vaccine and aired in March 2015 affected HPV uptake. Results The documentary led to a quick and substantial decrease in the monthly propensity to vaccinate, which dropped 3 percentage points—or about 50%—in response to the documentary. Responses differed substantially across subgroups, and girls from families with high socioeconomic status (SES) were more susceptible to the negative media coverage. Conclusions Susceptibility to negative media coverage varied substantially across subgroups, highlighting the need for policy makers to appropriately target and differentiate initiatives to improve vaccine compliance rates.

A Case of Myopericarditis and the HPV vaccine

2021 ◽  
Vol 9 (12) ◽  
Author(s):  
Angela Pegram ◽  
Tara Bush
Keyword(s):  
Human Papillomavirus ◽  
Social History ◽  
Hpv Vaccine ◽  
Package Insert ◽  
Human Papillomavirus Vaccine ◽  
T Wave ◽  
Dose Number ◽  
Males And Females ◽  
Artery Disease ◽  
Papillomavirus Vaccine

Introduction: Human Papillomavirus (HPV) is the underlying etiology of numerous cancers and genital warts in both males and females. Vaccines were developed against HPV to prevent transmission and arrest development of cancers caused by the virus. Gardasil 9â is the newest vaccine, covering 9 serotypes of HPV and is recommended by the CDC for both males and females over 9 years of age in a series of vaccinations. Myopericarditis (including myocarditis and pericarditis) is not reported as an adverse reaction in the Gardasil 9â package insert. Case Report A healthy 18-year-old male with no significant past medical or social history received dose number 3 of HPV vaccine at his physician’s office. Within 24 hours, he developed chills and a fever (normal HPV reactions) and then recovered without sequelae within 48 hours. Three days later, he developed crushing chest pain, with arm tingling and jaw pain. He was triaged directly to the emergency room where he had troponins of greater than 11000 and T wave inversions on his EKG. Other diagnostic tests and labs showed normal heart anatomy and no early coronary artery disease. He was diagnosed with myopericarditis by cardiology. He was treated and recovered fully within 3 months. Discussion Using the WHO tool for adverse vaccine reactions, this case has a consistent causal relationship with vaccination. This is the eleventh case of myopericarditis reported to the Vaccine Adverse Effects Reporting system for the HPV vaccine. Conclusion Although rare, myopericarditis should be considered as a possible adverse effect from the human papillomavirus vaccine.

scholarly journals High Human Papillomavirus Vaccine Acceptability and Cost-Effectiveness of the Chinese 2-Valent Vaccine Among Men Who Have Sex With Men: A Cross-Sectional Study in Shenyang, China

2021 ◽  
Vol 8 ◽  
Author(s):  
Ze-Hao Ye ◽  
Zhao-Zhen Liu ◽  
Si-Tong Cui ◽  
Zhen-Xing Chu ◽  
Yong-Jun Jiang ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Cost Effectiveness ◽  
Hpv Vaccine ◽  
Online Survey ◽  
Cost Effective ◽  
Hpv Infection ◽  
Human Papillomavirus Vaccine ◽  
Vaccine Acceptability ◽  
Cross Sectional ◽  
Sex With Men

Background: Despite the insupportable burden caused by the human papillomavirus (HPV) and high vaccine acceptability, vaccination programs are not currently available for men who have sex with men (MSM). We aimed to assess HPV infection by examining the willingness for vaccination among MSM and cost-effectiveness of the Chinese 2-valent HPV vaccine.Methods: We recruited MSM in Shenyang, China between July and December 2020 to conduct anal HPV testing and an online survey regarding HPV-related knowledge and vaccine acceptability. We performed a cost-effectiveness analysis to evaluate the incremental cost-effectiveness ratios (ICERs) of the Chinese 2-valent HPV vaccine.Results: A total of 234 participants completed the online survey; of those, 203 were successfully tested for HPV. The median age was 30 years [interquartile range (IQR): 23–38 years]. Most participants had at least undergraduate education (136/234, 58.1%). The acceptability rate for the free HPV vaccine was 57.7% (135/234). The prevalence of HPV types 16 and 18 was 14.9% (18/121) and 26.8% (22/82) in the willing and unwilling to vaccinate groups, respectively (P &gt; 0.05). The prevalence of high-risk HPV among participants aged &lt;30 and ≥50 years was 48.6 and 38.9%, respectively. Using the Chinese per capita gross domestic product (GDP) as a threshold, the Chinese 2-valent HPV vaccine would be a “very cost-effective” strategy, with an ICER value of USD 4,411. This evidence showed that the Chinese 2-valent HPV vaccine was more cost-effective than other imported vaccines.Conclusions: Targeted strategies should be utilized in MSM with different rates of vaccine acceptability. A pilot HPV vaccination program based on the Chinese 2-valent HPV vaccine for MSM is urgently warranted to reduce the burden of HPV and anal cancer.

scholarly journals 962. Trends in Cervical Pre-cancers by Race and Ethnicity During the Human Papillomavirus Vaccine Era, HPV Vaccine Impact Monitoring Project (HPV-IMPACT), United States, 2008–2016

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S29-S29
Author(s):  
Julia Gargano ◽  
Rayleen Lewis ◽  
Hillary Hunt ◽  
Nancy McClung ◽  
Nancy M Bennett ◽  
...  
Keyword(s):  
United States ◽  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
The United States ◽  
Adenocarcinoma In Situ ◽  
Human Papillomavirus Vaccine ◽  
Impact Monitoring ◽  
Vaccine Impact ◽  
Race Ethnicity ◽  
Papillomavirus Vaccine

Abstract Background Since human papillomavirus (HPV) vaccine introduction in the United States in 2006, cervical pre-cancer incidence has declined in young women, but pre-cancer trends have not been reported by race/ethnicity. We evaluated trends in cervical pre-cancers from 2008 to 2016 in non-Hispanic (NH) white, NH black, NH Asian, and Hispanic women identified through active population-based surveillance in the 5-site Human Papillomavirus Vaccine Impact Monitoring Project (HPV-IMPACT). Methods We analyzed data on cervical intraepithelial neoplasia (CIN) grades 2–3 and adenocarcinoma in situ (CIN2+) cases aged 20–39 years. Annual CIN2+ rates per 100,000 women were calculated stratified by race/ethnicity in 5-year age groups, using multiple imputation to account for 10% missing race/ethnicity data. Rates were also calculated using estimated numbers screened for cervical cancer to control for known declines in screening. Trends, evaluated using JoinPoint software, are presented as average annual percentage changes (AAPC) with 95% confidence intervals (CI). Results A total of 18,222 CIN2+ cases (62% NH white, 16% NH black, 16% Hispanic, 6% Asian) were reported from 2008 to 2016. CIN2+ rates among 20–24 year-olds declined significantly in all groups: NH white, AAPC: −14.2 (95% CI: −16.3, −12.1); NH black, AAPC: −15.5 (−19.5, −11.4); Asian, AAPC: −14.8 (−20.5, −8.8); Hispanic, AAPC: −14.3 (−17.9, −10.5). In 25–29 year olds, a significant decline was observed for NH whites only (AAPC: −2.4, [−4.0, −0.8]). No declines were seen in 30–34 or 35–39 year olds. Among screened 20–24 year-olds, significant but smaller declines were observed (AAPC: −9.8 to −8.4); no declines were observed in screened 25–29 year olds or older groups. Conclusion In this evaluation of CIN2+ trends by race/ethnicity during the HPV vaccine era, the significant declines in 20–24 year olds across all groups, including among screened women, is consistent with equitable vaccine impact on CIN2+. Disclosures All Authors: No reported Disclosures.

Bioethics Human Papillomavirus and HPV Vaccine

2019 ◽  
Author(s):  
Christine Shanahan Davies
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Ethical Issues ◽  
Social Issues ◽  
Scientific Evidence ◽  
Ethical Question ◽  
Clinical Aspects ◽  
Human Papillomavirus Vaccine ◽  
Family Nurse Practitioner ◽  
Papillomavirus Vaccine

This paper will discuss what the Human Papillomavirus (HPV) is. Ethical questions posed are “Should the HPV (Human Papillomavirus) vaccine be required? If yes at what age and should it be required for both boys and girls? During the paper another ethical question that will be discussed is, “On what basis should parents be permitted to refuse and be exempt from the mandate”? An analysis of the Human papillomavirus will explain what is HPV, how it is passed between people, any symptoms that could occur, and information about treatment, vaccines, and prevention. The role and responsibilities of the Family Nurse Practitioner, clinical aspects, scientific evidence, conflicts, social issues, contextual facts and stakeholders will all be discussed. In addition bioethical principles autonomy, informed consent, beneficence, non-malfeasance, and justice will be discussed that are relevant and applicable to the ethical issues associated with the Human papillomavirus and HPV vaccine.

Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance

Sexual Health ◽  
2010 ◽  
Vol 7 (3) ◽  
pp. 320 ◽  
Author(s):  
Michael S. Gold ◽  
Jim Buttery ◽  
Peter McIntyre
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Case Series ◽  
Vaccine Safety ◽  
Age Group ◽  
Human Papillomavirus Vaccine ◽  
Federally Funded ◽  
Conversion Disorders ◽  
Passive Surveillance System ◽  
Papillomavirus Vaccine

Australia was one of the first countries to licence a quadrivalent human papillomavirus (HPV) vaccine, rapidly followed by a federally funded program of universal vaccination of a broad age group of females through schools (12 to 18 years) and primary care (19 to 26 years). As of August 2009, more than 5.8 million doses of Gardasil® (quadrivalent; Merck, New Jersey, USA) have been distributed in Australia and a total of 1394 suspected adverse events following immunisation (AEFI) have been reported to the passive surveillance system. Most reports are of common and expected reactions. Case series of more uncommon and serious AEFI, both known to be potentially vaccine related (anaphylaxis, conversion disorders and lipoatrophy) and otherwise (multiple sclerosis and pancreatitis) have been published.

scholarly journals Correlates of Human Papillomavirus Vaccine Completion Among Adolescent Girl Initiators

2015 ◽  
Vol 54 (14) ◽  
pp. 1328-1333 ◽  
Author(s):  
Mahbubur Rahman ◽  
Tabassum H. Laz ◽  
Christine J. McGrath ◽  
Abbey B. Berenson
Keyword(s):  
Human Papillomavirus ◽  
Adolescent Girl ◽  
Human Papillomavirus Vaccine ◽  
Vaccine Completion ◽  
Papillomavirus Vaccine
Sign in / Sign up

Export Citation Format

Share Document